1. Home
  2. RUM vs DFTX Comparison

RUM vs DFTX Comparison

Compare RUM & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rumble Inc.

RUM

Rumble Inc.

HOLD

Current Price

$4.93

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$20.42

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
RUM
DFTX
Founded
2013
N/A
Country
United States
United States
Employees
135
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RUM
DFTX
Price
$4.93
$20.42
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$10.00
$40.25
AVG Volume (30 Days)
1.6M
1.6M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$209.98
N/A
Revenue Next Year
$40.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.62
$14.62
52 Week High
$10.99
$21.10

Technical Indicators

Market Signals
Indicator
RUM
DFTX
Relative Strength Index (RSI) 41.77 63.24
Support Level $4.67 $16.41
Resistance Level $7.02 N/A
Average True Range (ATR) 0.23 1.09
MACD 0.00 0.23
Stochastic Oscillator 35.42 82.47

Price Performance

Historical Comparison
RUM
DFTX

About RUM Rumble Inc.

Rumble Inc is a free-to-use video-sharing platform where users can watch, share, like, comment, and upload their own videos. Users can subscribe to channels to stay in touch with recent creator content and access video-on-demand uploaded, and live content streamed, by creators. Geographically, it generates a majority of its revenue from the United States.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: